J&J hopes to boost vax business with Crucell buy

The world's largest diversified healthcare group Johnson & Johnson said Wednesday it will buy Dutch biotechnology firm Crucell for €1.75 billion ($2.4 billion)--a move that will help it boost its vaccine business. J&J said Crucell's board has agreed to the takeover offer and has recommended the bid to its shareholders. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.